VPI-2690B
VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research[1].
Product Specifications
UNSPSC
12352203
Target
Integrin; TGF-β Receptor
Related Pathways
Cytoskeleton; TGF-beta/Smad
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Smiles
[VPI-2690B]
References & Citations
[1]Park CH, et al. TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis. Pharmaceuticals (Basel) . 2022 Nov 29;15 (12) :1485.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
More Discoveries
Explore Other Products
Browse additional items from our catalog
